GSK: EMA studying potential of Covid drug Xevudy

(CercleFinance.com) - The European Medicines Agency (EMA) yesterday announced that it has started evaluating the marketing authorisation application sent to it by GSK relating to the monoclonal antibody Xevudy (sotrovimab), developed in collaboration with Vir Biotechnology.


Xevudy is intended for the treatment of adults and adolescents with Covid who do not need additional oxygen therapy, but who are at increased risk of developing a severe form of the disease.

The EMA will assess the benefits and risks of Xevudy within a short period of time and may issue an opinion within two months.

If the benefits of Xevudy outweigh the risks, the EMA would contact the European Commission so that the marketing authorisation in all EU and EEA member states can be granted.



Copyright (c) 2021 CercleFinance.com. All rights reserved.